MD1558G2 - Metoda de profilaxie a insuficientei renale acute la mamifere cu aplicarea factorului de creştere de tip insulinic IGF-I - Google Patents

Metoda de profilaxie a insuficientei renale acute la mamifere cu aplicarea factorului de creştere de tip insulinic IGF-I Download PDF

Info

Publication number
MD1558G2
MD1558G2 MD96-0244A MD960244A MD1558G2 MD 1558 G2 MD1558 G2 MD 1558G2 MD 960244 A MD960244 A MD 960244A MD 1558 G2 MD1558 G2 MD 1558G2
Authority
MD
Moldova
Prior art keywords
igf
growth factor
insufficieny
prophylaxis
acute renal
Prior art date
Application number
MD96-0244A
Other languages
English (en)
Russian (ru)
Other versions
MD1558F2 (ro
Inventor
Ross G. Clark
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of MD1558F2 publication Critical patent/MD1558F2/ro
Publication of MD1558G2 publication Critical patent/MD1558G2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Invenţia se referă la medicină, şi anume la terapie.Esenţa metodei constă în aceea că mamiferului, inclusiv omului, i se administrează o cantitate eficientă a factorului de creştere de tip insulinic IGF-I. Administrarea IGF-I poate fi efectuată în combinaţie cu o proteină de aglutinare IGF şi/sau cu o cantitate eficientă de hormon de creştere. Preferabil în calitate de IGF-I se foloseşte IGF-I uman.
MD96-0244A 1992-09-22 1993-09-15 Metoda de profilaxie a insuficientei renale acute la mamifere cu aplicarea factorului de creştere de tip insulinic IGF-I MD1558G2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/949,594 US5273961A (en) 1992-09-22 1992-09-22 Method of prophylaxis of acute renal failure
PCT/US1993/008734 WO1994006461A1 (en) 1992-09-22 1993-09-15 Method of prophylaxis of acute renal failure

Publications (2)

Publication Number Publication Date
MD1558F2 MD1558F2 (ro) 2000-11-30
MD1558G2 true MD1558G2 (ro) 2001-05-31

Family

ID=25489299

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0244A MD1558G2 (ro) 1992-09-22 1993-09-15 Metoda de profilaxie a insuficientei renale acute la mamifere cu aplicarea factorului de creştere de tip insulinic IGF-I

Country Status (8)

Country Link
US (1) US5273961A (ro)
EP (1) EP0661994A1 (ro)
JP (1) JP3577313B2 (ro)
AU (1) AU674535B2 (ro)
CA (1) CA2144185C (ro)
MD (1) MD1558G2 (ro)
NZ (1) NZ256315A (ro)
WO (1) WO1994006461A1 (ro)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU690941B2 (en) * 1993-11-15 1998-05-07 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering IGF-I and IGFBP-3
US6812208B2 (en) 1993-12-23 2004-11-02 Neuronz Ltd. Methods to improve neural outcome
US5622715A (en) * 1994-06-10 1997-04-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of improving renal function
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
JPH0995455A (ja) * 1995-09-29 1997-04-08 Sumitomo Pharmaceut Co Ltd 腎機能改善剤
EP0956041A1 (en) * 1996-09-16 1999-11-17 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US7074762B2 (en) * 1998-01-05 2006-07-11 Washington University Composition and method for improving function of embryonic kidney transplants
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
ES2329220T3 (es) * 1999-01-06 2009-11-24 Genentech, Inc. Variantes mutantes del factor de crecimiento similar a insulina (igf) i.
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
DE60217066T4 (de) * 2001-02-09 2010-07-01 Genentech, Inc., South San Francisco Kristallisierung von igf-1
EP1401808B1 (en) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe analogs and peptidomimetics
US7714020B2 (en) * 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
JP2008511838A (ja) * 2004-08-30 2008-04-17 テルシカ・インク インシュリン様成長因子欠乏疾患の診断及び治療のための方法及び装置
DK1831699T3 (da) * 2004-12-20 2010-03-15 Antibodyshop As Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
WO2008017306A1 (en) * 2006-08-07 2008-02-14 Antibodyshop A/S Diagnostic test to exclude significant renal injury
EP2137538B1 (en) * 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostic test for renal injury
EP2215481B2 (en) * 2007-11-15 2017-01-18 Bioporto Diagnostics A/S Diagnostic use of individual molecular forms of a biomarker
RU2414253C1 (ru) * 2009-11-16 2011-03-20 Сергей Петрович Лысенков Способ профилактики почечной недостаточности при комплексной коррекции состояния больных с ожирением
WO2011156389A2 (en) * 2010-06-07 2011-12-15 The Regents Of The University Of California The islet amyloid polypeptide toxic oligomer is a biomarker of heart or kidney failure in type-2 diabetes mellitus
JP2016512201A (ja) * 2013-03-08 2016-04-25 アッヴィ・インコーポレイテッド 急性腎障害の治療方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327503B1 (en) * 1988-02-05 1993-03-10 Ciba-Geigy Ag Use of igf i in the manufacture of a medicament for the treatment of renal diseases
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Тареев И. Е. и др. Справочник по нефрологии. Москва, Медицина, 1986, p. 254-261 *

Also Published As

Publication number Publication date
WO1994006461A1 (en) 1994-03-31
MD1558F2 (ro) 2000-11-30
EP0661994A1 (en) 1995-07-12
CA2144185A1 (en) 1994-03-31
JP3577313B2 (ja) 2004-10-13
US5273961A (en) 1993-12-28
CA2144185C (en) 2008-07-15
NZ256315A (en) 1997-06-24
JPH08501778A (ja) 1996-02-27
AU4924693A (en) 1994-04-12
AU674535B2 (en) 1997-01-02

Similar Documents

Publication Publication Date Title
MD1558F2 (ro) Metoda de profilaxie a insuficientei renale acute la mamifere cu aplicarea factorului de crestere de tip insulinic IGF-I
ES2180635T3 (es) Metodo para reducir la grasa corporal en animales mediante la administracion de acido linoleico conjugado.
EP0274431A3 (en) Drug delivery compositions and methods
CA2102429A1 (en) Bone growth factors and inhibitors of bone resorption for promoting bone formation
FI970747A0 (fi) Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa
ZA843062B (en) Secretion of correctly processed human growth hormone in e.coli and pseudomonas
EP1025853A3 (en) Pharmaceutical composition containing S-nitroso-heme proteins and use thereof
IL76932A (en) Synergistic pharmaceutical analgesic compositions containing dihydrocodeine and ibuprofen
IL84946A0 (en) Drug delivery compositions and their preparation
GR3023613T3 (en) Hepatocyte growth stimulation with hepatocyte growth factor and gamma-interferon.
AU3139097A (en) Methods of preventing skeletal problems in poultry
AU1025988A (en) Pharmaceutical composition of follicle stimulating hormone and luteinizing hormone
HU9302407D0 (en) Preparatives for treating osteoporosis
NO940180L (no) Anvendelse av IGF-I
ATE183651T1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
IE860212L (en) Polypeptide factors from colostrum
TW263437B (ro)
WO1989000166A3 (en) Growth hormone related peptide
IL103862A (en) Stabilized pharmaceutical composition of non-glycosylated recombinant human IL2 in reduced form and its preparation process
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
EP0342416A3 (en) Medicine
IL84758A0 (en) Peptides stimulating the release of pituitary growth hormone in fish and amphibians,and pharmaceutical compositions containing them
SE9002731D0 (sv) Product comprising growth factor
FR2432869A1 (fr) Compositions pour le traitement de l'osteoporose associant la calcitonine et le phosphore

Legal Events

Date Code Title Description
PD99 Pending application
MK4A Patent for invention expired